CA
NZ
UK
AU
IND
US
…
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Biomotion Sciences (NASDAQ: SLXN) is sparse, so business details and financial disclosures are limited. If it is an early-stage life‑sciences company, long-term growth may depend on clinical progress, regulatory approvals, licensing or commercial adoption, which could attract investors seeking exposure to development-stage technologies.
Material risks include limited disclosure and liquidity, early-stage and regulatory uncertainty, potential dilution from financing, and execution risk in clinical or commercialization efforts.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -11.91M | -16.51M | -5.08M | -3.46M | -0.76M |
| Minority interest | 0.00M | 0.08M | 0.17M | 0.27M | - |
| Net income | -11.91M | -16.44M | -4.94M | -3.21M | -0.76M |
| Selling general administrative | 4.48M | 6.73M | 0.93M | 0.58M | - |
| Gross profit | -0.01M | -0.03M | - | - | - |
| Reconciled depreciation | 0.01M | 0.03M | 0.04M | 0.06M | - |
| Ebit | -11.90M | -16.50M | -5.07M | -3.38M | -0.94M |
| Ebitda | -11.88M | -16.48M | -5.02M | -3.32M | -0.76M |
| Depreciation and amortization | 0.01M | 0.03M | 0.04M | 0.06M | - |
| Operating income | 11.63M | -12.57M | -4.68M | -3.86M | -0.94M |
| Other operating expenses | 11.63M | 12.57M | 4.68M | 3.86M | 0.94M |
| Interest expense | 0.01M | 0.05M | 0.01M | 0.09M | - |
| Tax provision | 0.00M | 0.01M | 0.03M | 0.02M | - |
| Interest income | 0.14M | 0.00M | 0.15M | 0.11M | - |
| Net interest income | 0.13M | -4.84M | 0.14M | 0.03M | - |
| Income tax expense | 0.00M | 0.01M | 0.03M | 0.02M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | -11.63M | 12.57M | 4.68M | 3.86M | 0.94M |
| Cost of revenue | 0.01M | 0.03M | - | - | - |
| Total other income expense net | -23.54M | -3.94M | -0.40M | 0.40M | 0.19M |
| Net income from continuing ops | -11.91M | -16.52M | -5.11M | -3.49M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7.21M | 2.86M | 5.26M | 9.33M | 115.41M |
| Other current assets | 0.65M | 1.06M | 0.38M | 0.58M | 0.37M |
| Total liab | 4.61M | 6.85M | 17.31M | 16.41M | 0.51M |
| Total stockholder equity | 2.60M | -3.99M | -15.48M | -10.66M | 114.91M |
| Other current liab | 1.79M | 1.43M | 1.76M | 1.25M | 0.35M |
| Common stock | 0.04M | 0.00M | 0.00M | 0.00M | 115.00M |
| Capital stock | 0.04M | 0.00M | 0.00M | 0.00M | - |
| Retained earnings | -55.17M | -43.25M | -26.81M | -21.87M | -0.95M |
| Cash | 5.99M | 1.19M | 4.59M | 8.26M | 0.04M |
| Total current liabilities | 2.76M | 3.52M | 2.20M | 1.61M | 0.35M |
| Net debt | -5.52M | 3.30M | -4.42M | -7.99M | -0.04M |
| Short term debt | 0.18M | 1.16M | 0.11M | 0.12M | - |
| Short long term debt | - | 1.00M | - | - | - |
| Short long term debt total | 0.47M | 4.49M | 0.17M | 0.27M | - |
| Other stockholder equity | 57.73M | 39.26M | 11.33M | 11.20M | 0.86M |
| Total current assets | 6.64M | 2.25M | 4.98M | 8.84M | 0.41M |
| Short term investments | - | 0.04M | - | - | - |
| Long term debt | 1.57M | 2.96M | - | - | - |
| Accounts payable | 0.79M | 0.93M | 0.32M | 0.24M | - |
| Non currrent assets other | 0.08M | 0.05M | 0.03M | 0.03M | - |
| Non current assets total | 0.58M | 0.61M | 0.28M | 0.49M | 115.01M |
| Capital lease obligations | 0.47M | 0.53M | 0.17M | 0.27M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.01M | -0.02M | 0.57M | -0.52M | - |
| Total cashflows from investing activities | -0.01M | -0.02M | 0.57M | -0.52M | - |
| Net borrowings | -0.70M | -0.25M | 0.00M | - | - |
| Total cash from financing activities | 15.64M | 5.10M | 0.52M | 2.75M | 116.40M |
| Net income | -11.91M | -16.52M | -5.11M | -3.49M | -0.76M |
| Change in cash | 4.80M | -3.38M | -3.66M | -1.77M | -0.01M |
| Begin period cash flow | 1.27M | 4.64M | 8.31M | 10.08M | 0.05M |
| End period cash flow | 6.08M | 1.27M | 4.64M | 8.31M | 0.04M |
| Total cash from operating activities | -10.82M | -8.40M | -4.53M | -3.33M | -1.41M |
| Issuance of capital stock | 18.68M | 3.05M | 0.52M | 2.75M | - |
| Depreciation | 0.01M | 0.03M | 0.04M | 0.06M | - |
| Other cashflows from investing activities | -0.01M | - | 0.08M | - | - |
| Change to account receivables | - | - | 0.02M | -0.04M | - |
| Other cashflows from financing activities | 15.64M | 2.30M | 0.52M | 2.75M | -2.55M |
| Capital expenditures | 0.01M | 0.02M | 0.01M | 0.04M | 0.00M |
| Change in working capital | 0.60M | -1.58M | 0.09M | 0.24M | -0.47M |
| Stock based compensation | 0.13M | 5.86M | 0.13M | 0.12M | - |
| Other non cash items | 0.34M | 3.82M | 0.32M | -0.27M | -0.18M |
| Free cash flow | -10.83M | -8.42M | -4.54M | -3.38M | -1.41M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| SLXN Biomotion Sciences Ordinary Shares |
0.00 2.04% |
0.15 | - | - | - | 47.99 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 |
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
The Goldyne Savad Inst. of Gene Therapy, Jerusalem, Israel, 9112001
972 2 674 3430
13
| Name | Title | Year Born |
|---|---|---|
| Mr. Ilan Hadar M.B.A. | Chairman & CEO | 1969 |
| Ms. Mirit Horenshtein Hadar | EVP of Finance Affairs, CFO & Secretary | 1984 |
| Dr. Mitchell Shirvan M.B.A., Ph.D. | Chief Scientific & Development Officer | 1954 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...